Table 1. Pharmacological and biochemical targets for cardioprotection involving mitochondrial activities.
CPT-1, carnitine palmitoyl transferase-1; DEVD-CHO, acetyl-Asp-Glu-Val-Asp-CHO; PDH, pyruvate dehydrogenase.
Treatment | Effect(s) | Comment(s) | Reference(s) |
---|---|---|---|
General Treatments | |||
Fasting and diet | Complex | Lowers glycogen stores | [205–207] |
Brief incubation at low O2 | Complex | Ischaemic preconditioning | [208] |
Glucose/insulin | Promote glycolysis | May induce protein phosphorylation | [209–211] |
Pyruvate | Metabolic substrate, inhibits fatty acid oxidation | Also protects against ROS | [212,213] |
Inhibitors of fatty acid metabolism | |||
Trimetazidine, ranolazine | Inhibit fatty acid dehydrogenases | [214] | |
Oxfenicine and other CPT-I inhibitors | Inhibit fatty acid entry into mitochondria | [206,215] | |
Malonate | Inhibits fatty acid oxidation | [216,217] | |
Dichloroacetate | Inhibits PDH kinase | Promotes glucose utilization | [218] |
Carnitine and its derivatives | Lowers acetyl-CoA/free CoA, increasing free CoA | Promotes glycolysis by decreasing inhibition of PDH | [219,220] |
Niacin | Reduces plasma non-esterified fatty acids | May help NAD recovery | [29,221] |
Inhibitors of mitochondrial respiration | |||
Amytal, rotenone | Inhibits electron flow, complex I | Decreases ROS production | [30,222] |
Myxothiazole | Inhibits electron flow, complex III | Antimycin and CN− not protective | [223] |
Uncouplers (dinitrophenol) | Decrease mitochondrial membrane potential | Time/dose dependence, to avoid energy wastage | [223] |
Oligomycin | Inhibits F1Fo-ATPase | Time/dose dependence, to avoid ATP depletion | [224] |
Inhibitors of ion movement | |||
Ruthenium Red | Blocks mitochondrial Ca2+ import | Can also block the sarcoplasmic reticulum Ca2+-channel | [225,226] |
Nisoldipine; gallopamil | Block Ca2+ entry into cytoplasm | [227–229] | |
Tetrodotoxin | Blocks Na+ entry into cytoplasm | Damages mitochondria during ischaemia | [63] |
Amiloride | Blocks cytoplasmic Na+/H+ exchanger | Prevents Ca2+ overload, therefore protects against reoxygenation-induced hypercontracture | [150,230,231] |
Diltiazem; SEA0400 (5-ethoxyaniline derivative) | Inhibits mitochondrial Na+/Ca2+ exchange | [232–234] | |
Diazoxide; nicorandil | K+-channel opener | Reversed by 5-OH decanoate, decreases ROS and plays roles in other undefined mechanisms | [59,66] |
Inhibitors of cell damage mechanisms | |||
Cyclosporin | Prevents MPT opening | May also inhibit Ca2+/CAM-dependent protein phosphatase (calcineurin) | [197,235] |
Propofol | Traps ROS | ROS promote MPT | [199,236] |
DEVD-CHO | Caspase 3 inhibitor (prevents downstream steps in apoptosis) | Only partially effective | [203] |
Dipyridamole; carvedilol; natural compounds such as vitamin E and resveratrol; N-acetylcysteine | Antioxidants | Restores GSSG/GSH balance | [237–240] |
Chloramphenicol | Inhibits cytochrome P450 mono-oxygenases | Also inhibits mitochondrial protein synthesis | [241] |
Effectors of signalling pathways | |||
Sevoflurane and other anaesthetics | NADH increase on ischaemia is reduced, and total [NAD]+[NADH] is preserved | Uncontrolled effects on membrane permeability to ions | [242] |
Bromoenol-lactone | Inhibits mitochondrial Ca2+-independent phospholipases | [243] | |
Soluble factors released from preconditioned heart | Includes adenosine, catecholamines, NO, prostanoids, endorphins | See review | [244] |
Adenosine | Many effects, including modulation of mK+ATP channel and protein kinase C | Other additional protective mechanisms include phosphorylation to 5′-AMP during reperfusion | [245,246] |